Effects of 1,25(OH)₂D₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents.
Nutrients. 2017 Jan 23;9(1). pii: E87. doi: 10.3390/nu9010087.
Abu El Maaty MA 1, Wölfl S 2.
- 1 Institut für Pharmazie und Molekulare Biotechnologie (IPMB), Universität Heidelberg, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany. abu.el.maaty at gmail.com.
- 2 Institut für Pharmazie und Molekulare Biotechnologie (IPMB), Universität Heidelberg, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany. wolfl at uni-hd.de.
VitaminDWiki suspects that regular vitamin D will do as well as activated vitamin D discussed in this PDF
- Both Vitamin D and Vitamin C fight cancers and aid anticancer drugs – May 2018
- Vitamin D fights treatment-resistant cancers (petrie dish) – June 2019
- this may be the reason that Vitamin D helps Chemo
- Cancer - After diagnosis has the following chart (2X chemo improvement with vitamin D)
- Hypothesis – Chemotherapy can be aided by Vitamin D – March 2016
- Reduced palliative cancer pain after Vitamin D supplementation – April 2016
- Breast Cancer Chemotherapy dropped Vitamin D levels by 6 nanograms – Nov 2015
Appears that Vitamin D supplements are needed during some Chemotherapies
- 3X less pelvic inflammation from cancer radiation if high level of vitamin D – Feb 2015
Vitamin D helps with radiation theraphy as well
- Hypothesis: Chemo brain and other cognitive impairements are associated with low vitamin D
- Cancer Chemotherapy and vitamin D – Review March 2013
- Active form of vitamin D appears to help prevent and treat some cancers – Feb 2011
- Metastatic Cancer probably reduced by vitamin D - many studies
- click on chart for details
The diverse effects of 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), the bio-active form of vitamin D, on cancer cell metabolism and proliferation has made it an interesting candidate as a supporting therapeutic option in cancer treatment. An important strategy in cancer therapy is the use of combination chemotherapy to overcome drug resistance associated with numerous anti-cancer agents and to provide better means of avoiding undesirable side effects. This complex strategy is widely adopted by oncologists and several established "cocktails" of chemotherapeutics are routinely administered to cancer patients. Among the principles followed in designing such treatment regimens is the use of drugs with different mechanisms of action to overcome the issue of tumor heterogeneity and to evade resistance. In light of the profound and diverse effects of 1,25(OH)₂D₃ reported by in vitro and in vivo studies, we discuss how these effects could support the use of this molecule in combination with "classical" cytotoxic drugs, such as platins and anti-metabolites, for the treatment of solid and hematological tumors. We also examine recent evidence supporting synergistic activities with other promising anti-cancer drug candidates, and postulate mechanisms through which 1,25(OH)₂D₃ may help evade chemoresistance.
PMID: 28124999 PMCID: PMC5295131 DOI: 10.3390/nu9010087